Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

Years of research involving hundreds of thousands of children have found no link between autism and vaccines. HealthDay News — The US Centers for Disease Control and Prevention (CDC) is preparing to ...

Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...

The survey revealed that 18% of young adults aged 18 to 29 years needed to borrow money to pay health care costs. Adults aged 30 to 49 years reported similar rates. However, only 9 and 2% of Americans ...

Several lots of intravenous and subcutaneous immune globulin have been voluntarily withdrawn by the manufacturers as a precautionary measure due to increased reports of allergic/hypersensitivity type ...

“Our trial showed that treating male partners with a week of oral metronidazole and topical clindamycin, together with treatment of women, resulted in a lower rate of recurrence of bacterial vaginosis ...

Variation in CGM bias by postprandial test, with glycemic index for commercial fruit smoothie higher with CGM versus capillary sampling ...

OKYO Pharma has filed a Fast Track designation application with the Food and Drug Administration (FDA) for urcosimod in the treatment of neuropathic ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Researchers found no significant change in the prevalence of diabetes, from 12.8% in 2013-2014 to 14.1% in 2021-2023.